B
AstraZeneca PLC
AZN
$75.72
$0.5450.73%
B
Buy
3/27/2024Upgraded
AstraZeneca PLC (AZN) was upgraded to B from B- on 3/27/2024 due to an increase in the total return index and volatility index.
AstraZeneca PLC (AZN) was upgraded to B from B- on 3/27/2024 due to an increase in the total return index and volatility index.
B
Buy
2/21/2024Upgraded
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 2/21/2024 due to an increase in the dividend index, valuation index and volatility index.
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 2/21/2024 due to an increase in the dividend index, valuation index and volatility index.
C
Hold
1/24/2024Downgrade
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 1/24/2024 due to a decline in the volatility index and valuation index.
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 1/24/2024 due to a decline in the volatility index and valuation index.
B
Buy
1/4/2024Upgraded
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 1/4/2024 due to an increase in the volatility index.
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 1/4/2024 due to an increase in the volatility index.
C
Hold
11/22/2023Downgrade
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 11/22/2023 due to a decline in the growth index, dividend index and volatility index. Earnings per share declined from $1.17 to $0.88, and EBIT declined 2.65% from $2.6B to $2.53B.
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 11/22/2023 due to a decline in the growth index, dividend index and volatility index. Earnings per share declined from $1.17 to $0.88, and EBIT declined 2.65% from $2.6B to $2.53B.
B
Buy
10/27/2023Downgrade
AstraZeneca PLC (AZN) was downgraded to B- from B on 10/27/2023 due to a significant decline in the total return index, volatility index and efficiency index. Total capital declined 0.11% from $68.28B to $68.21B.
AstraZeneca PLC (AZN) was downgraded to B- from B on 10/27/2023 due to a significant decline in the total return index, volatility index and efficiency index. Total capital declined 0.11% from $68.28B to $68.21B.
B
Buy
2/23/2023Upgraded
AstraZeneca PLC (AZN) was upgraded to B from B- on 2/23/2023 due to a large increase in the valuation index, dividend index and efficiency index. Total capital increased 2.66% from $66.43B to $68.19B.
AstraZeneca PLC (AZN) was upgraded to B from B- on 2/23/2023 due to a large increase in the valuation index, dividend index and efficiency index. Total capital increased 2.66% from $66.43B to $68.19B.
B
Buy
2/1/2023Downgrade
AstraZeneca PLC (AZN) was downgraded to B- from B on 2/1/2023 due to a decline in the total return index.
AstraZeneca PLC (AZN) was downgraded to B- from B on 2/1/2023 due to a decline in the total return index.
B
Buy
1/17/2023Upgraded
AstraZeneca PLC (AZN) was upgraded to B from B- on 1/17/2023 due to a significant increase in the total return index and volatility index.
AstraZeneca PLC (AZN) was upgraded to B from B- on 1/17/2023 due to a significant increase in the total return index and volatility index.
B
Buy
11/14/2022Upgraded
AstraZeneca PLC (AZN) was upgraded to B- from C on 11/14/2022 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.23 to $1.05, net income increased 355.56% from $360M to $1.64B, and operating cash flow increased 134.78% from $1.25B to $2.93B.
AstraZeneca PLC (AZN) was upgraded to B- from C on 11/14/2022 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.23 to $1.05, net income increased 355.56% from $360M to $1.64B, and operating cash flow increased 134.78% from $1.25B to $2.93B.
C
Hold
4/29/2022Downgrade
AstraZeneca PLC (AZN) was downgraded to C from C+ on 4/29/2022 due to a noticeable decline in the growth index, dividend index and volatility index. EBIT declined 53.25% from $1.88B to $878M, and total revenue declined 5.17% from $12.01B to $11.39B.
AstraZeneca PLC (AZN) was downgraded to C from C+ on 4/29/2022 due to a noticeable decline in the growth index, dividend index and volatility index. EBIT declined 53.25% from $1.88B to $878M, and total revenue declined 5.17% from $12.01B to $11.39B.
C
Hold
3/15/2022Upgraded
AstraZeneca PLC (AZN) was upgraded to C+ from C on 3/15/2022 due to a noticeable increase in the growth index, total return index and dividend index. EBIT increased 2,190.24% from $82M to $1.88B, earnings per share increased from -$1.1043 to -$0.2243, and total revenue increased 21.74% from $9.87B to $12.01B.
AstraZeneca PLC (AZN) was upgraded to C+ from C on 3/15/2022 due to a noticeable increase in the growth index, total return index and dividend index. EBIT increased 2,190.24% from $82M to $1.88B, earnings per share increased from -$1.1043 to -$0.2243, and total revenue increased 21.74% from $9.87B to $12.01B.
C
Hold
2/11/2022Downgrade
AstraZeneca PLC (AZN) was downgraded to C from C+ on 2/11/2022 due to a noticeable decline in the total return index and dividend index.
AstraZeneca PLC (AZN) was downgraded to C from C+ on 2/11/2022 due to a noticeable decline in the total return index and dividend index.
C
Hold
11/15/2021Downgrade
AstraZeneca PLC (AZN) was downgraded to C+ from B on 11/15/2021 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 400.36% from $550M to -$1.65B, earnings per share declined from $0.4192 to -$1.1043, and EBIT declined 93.15% from $1.2B to $82M.
AstraZeneca PLC (AZN) was downgraded to C+ from B on 11/15/2021 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 400.36% from $550M to -$1.65B, earnings per share declined from $0.4192 to -$1.1043, and EBIT declined 93.15% from $1.2B to $82M.
B
Buy
3/4/2021Downgrade
AstraZeneca PLC (AZN) was downgraded to B from B+ on 3/4/2021 due to a decline in the volatility index and total return index.
AstraZeneca PLC (AZN) was downgraded to B from B+ on 3/4/2021 due to a decline in the volatility index and total return index.
B
Buy
2/17/2021Upgraded
AstraZeneca PLC (AZN) was upgraded to B+ from B on 2/17/2021 due to a substantial increase in the growth index, solvency index and valuation index. Earnings per share increased from $0.49 to $0.7713, debt to equity declined from 1.98 to 1.42, and total revenue increased 12.65% from $6.58B to $7.41B.
AstraZeneca PLC (AZN) was upgraded to B+ from B on 2/17/2021 due to a substantial increase in the growth index, solvency index and valuation index. Earnings per share increased from $0.49 to $0.7713, debt to equity declined from 1.98 to 1.42, and total revenue increased 12.65% from $6.58B to $7.41B.
B
Buy
11/9/2020Upgraded
AstraZeneca PLC (AZN) was upgraded to B from B- on 11/9/2020 due to a large increase in the growth index, valuation index and solvency index. Operating cash flow increased 75.19% from $1.04B to $1.82B, the quick ratio increased from 0.62 to 0.76, and total revenue increased 4.83% from $6.28B to $6.58B.
AstraZeneca PLC (AZN) was upgraded to B from B- on 11/9/2020 due to a large increase in the growth index, valuation index and solvency index. Operating cash flow increased 75.19% from $1.04B to $1.82B, the quick ratio increased from 0.62 to 0.76, and total revenue increased 4.83% from $6.28B to $6.58B.
B
Buy
10/6/2020Downgrade
AstraZeneca PLC (AZN) was downgraded to B- from B on 10/6/2020 due to a major decline in the total return index.
AstraZeneca PLC (AZN) was downgraded to B- from B on 10/6/2020 due to a major decline in the total return index.
B
Buy
9/18/2020Upgraded
AstraZeneca PLC (AZN) was upgraded to B from B- on 9/18/2020 due to an increase in the total return index, valuation index and volatility index.
AstraZeneca PLC (AZN) was upgraded to B from B- on 9/18/2020 due to an increase in the total return index, valuation index and volatility index.
B
Buy
8/28/2020Downgrade
AstraZeneca PLC (AZN) was downgraded to B- from B on 8/28/2020 due to a noticeable decline in the total return index and efficiency index.
AstraZeneca PLC (AZN) was downgraded to B- from B on 8/28/2020 due to a noticeable decline in the total return index and efficiency index.
B
Buy
7/31/2020Upgraded
AstraZeneca PLC (AZN) was upgraded to B from C+ on 7/31/2020 due to a major increase in the total return index, valuation index and dividend index.
AstraZeneca PLC (AZN) was upgraded to B from C+ on 7/31/2020 due to a major increase in the total return index, valuation index and dividend index.
C
Hold
6/5/2020Upgraded
AstraZeneca PLC (AZN) was upgraded to C+ from C on 6/5/2020 due to an increase in the total return index and efficiency index.
AstraZeneca PLC (AZN) was upgraded to C+ from C on 6/5/2020 due to an increase in the total return index and efficiency index.
C
Hold
4/30/2020Downgrade
AstraZeneca PLC (AZN) was downgraded to C from C+ on 4/30/2020 due to a noticeable decline in the solvency index, dividend index and valuation index. Debt to equity increased from 1.52 to 1.9, and the quick ratio declined from 0.63 to 0.56.
AstraZeneca PLC (AZN) was downgraded to C from C+ on 4/30/2020 due to a noticeable decline in the solvency index, dividend index and valuation index. Debt to equity increased from 1.52 to 1.9, and the quick ratio declined from 0.63 to 0.56.
C
Hold
4/6/2020Downgrade
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 4/6/2020 due to a decline in the total return index, volatility index and valuation index.
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 4/6/2020 due to a decline in the total return index, volatility index and valuation index.
B
Buy
3/20/2020Upgraded
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 3/20/2020 due to an increase in the valuation index and solvency index.
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 3/20/2020 due to an increase in the valuation index and solvency index.
C
Hold
3/5/2020Downgrade
AstraZeneca PLC (AZN) was downgraded to C+ from B on 3/5/2020 due to a substantial decline in the valuation index, efficiency index and growth index.
AstraZeneca PLC (AZN) was downgraded to C+ from B on 3/5/2020 due to a substantial decline in the valuation index, efficiency index and growth index.
B
Buy
7/26/2019Upgraded
AstraZeneca PLC (AZN) was upgraded to B from B- on 7/26/2019 due to an increase in the growth index, solvency index and dividend index. Operating cash flow increased 326.87% from -$387M to $878M, the quick ratio increased from 0.57 to 0.74, and debt to equity declined from 2.06 to 1.46.
AstraZeneca PLC (AZN) was upgraded to B from B- on 7/26/2019 due to an increase in the growth index, solvency index and dividend index. Operating cash flow increased 326.87% from -$387M to $878M, the quick ratio increased from 0.57 to 0.74, and debt to equity declined from 2.06 to 1.46.
B
Buy
6/20/2019Upgraded
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 6/20/2019 due to an increase in the total return index.
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 6/20/2019 due to an increase in the total return index.
C
Hold
5/1/2019Downgrade
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 5/1/2019 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 117.4% from $2.22B to -$387M, earnings per share declined from $0.8161 to $0.468, and total revenue declined 14.43% from $6.42B to $5.49B.
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 5/1/2019 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 117.4% from $2.22B to -$387M, earnings per share declined from $0.8161 to $0.468, and total revenue declined 14.43% from $6.42B to $5.49B.
B
Buy
11/14/2018Downgrade
AstraZeneca PLC (AZN) was downgraded to B- from B on 11/14/2018 due to a large decline in the growth index, dividend index and valuation index. EBIT declined 15.2% from $855M to $725M.
AstraZeneca PLC (AZN) was downgraded to B- from B on 11/14/2018 due to a large decline in the growth index, dividend index and valuation index. EBIT declined 15.2% from $855M to $725M.
B
Buy
8/17/2018Upgraded
AstraZeneca PLC (AZN) was upgraded to B from B- on 8/17/2018 due to an increase in the volatility index and solvency index.
AstraZeneca PLC (AZN) was upgraded to B from B- on 8/17/2018 due to an increase in the volatility index and solvency index.
B
Buy
7/27/2018Upgraded
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 7/27/2018 due to a major increase in the growth index, dividend index and volatility index. Operating cash flow increased 146.43% from -$140M to $65M, EBIT increased 123.82% from $382M to $855M, and earnings per share increased from $0.2686 to $0.27.
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 7/27/2018 due to a major increase in the growth index, dividend index and volatility index. Operating cash flow increased 146.43% from -$140M to $65M, EBIT increased 123.82% from $382M to $855M, and earnings per share increased from $0.2686 to $0.27.
C
Hold
7/18/2018Upgraded
AstraZeneca PLC (AZN) was upgraded to C+ from C on 7/18/2018 due to an increase in the total return index and volatility index.
AstraZeneca PLC (AZN) was upgraded to C+ from C on 7/18/2018 due to an increase in the total return index and volatility index.
C
Hold
7/3/2018Downgrade
AstraZeneca PLC (AZN) was downgraded to C from C+ on 7/3/2018 due to a decline in the total return index.
AstraZeneca PLC (AZN) was downgraded to C from C+ on 7/3/2018 due to a decline in the total return index.
C
Hold
5/18/2018Downgrade
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 5/18/2018 due to a decline in the solvency index, dividend index and growth index. Operating cash flow declined 114.04% from $997M to -$140M, earnings per share declined from $1.0276 to $0.2686, and EBIT declined 58.7% from $925M to $382M.
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 5/18/2018 due to a decline in the solvency index, dividend index and growth index. Operating cash flow declined 114.04% from $997M to -$140M, earnings per share declined from $1.0276 to $0.2686, and EBIT declined 58.7% from $925M to $382M.
B
Buy
5/10/2018Upgraded
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 5/10/2018 due to an increase in the volatility index and valuation index.
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 5/10/2018 due to an increase in the volatility index and valuation index.
C
Hold
4/20/2018Downgrade
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 4/20/2018 due to a decline in the valuation index and volatility index.
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 4/20/2018 due to a decline in the valuation index and volatility index.
B
Buy
3/29/2018Upgraded
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 3/29/2018 due to an increase in the efficiency index, dividend index and volatility index. Net income increased 89.65% from $686M to $1.3B, and total capital increased 3.5% from $33.31B to $34.48B.
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 3/29/2018 due to an increase in the efficiency index, dividend index and volatility index. Net income increased 89.65% from $686M to $1.3B, and total capital increased 3.5% from $33.31B to $34.48B.
C
Hold
2/22/2018Downgrade
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 2/22/2018 due to a decline in the volatility index and valuation index.
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 2/22/2018 due to a decline in the volatility index and valuation index.
B
Buy
11/28/2017Upgraded
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 11/28/2017 due to an increase in the total return index, volatility index and solvency index.
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 11/28/2017 due to an increase in the total return index, volatility index and solvency index.
C
Hold
11/13/2017Downgrade
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 11/13/2017 due to a decline in the dividend index and valuation index.
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 11/13/2017 due to a decline in the dividend index and valuation index.
B
Buy
11/7/2017Upgraded
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 11/7/2017 due to an increase in the volatility index and total return index.
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 11/7/2017 due to an increase in the volatility index and total return index.
C
Hold
8/24/2017Downgrade
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 8/24/2017 due to a decline in the total return index.
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 8/24/2017 due to a decline in the total return index.
B
Buy
7/28/2017Upgraded
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 7/28/2017 due to a large increase in the growth index, valuation index and dividend index. Operating cash flow increased 184.09% from $88M to $250M, and EBIT increased 8.94% from $1.02B to $1.11B.
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 7/28/2017 due to a large increase in the growth index, valuation index and dividend index. Operating cash flow increased 184.09% from $88M to $250M, and EBIT increased 8.94% from $1.02B to $1.11B.
C
Hold
6/21/2017Upgraded
AstraZeneca PLC (AZN) was upgraded to C+ from C on 6/21/2017 due to a large increase in the total return index and volatility index.
AstraZeneca PLC (AZN) was upgraded to C+ from C on 6/21/2017 due to a large increase in the total return index and volatility index.
C
Hold
3/9/2017Upgraded
AstraZeneca PLC (AZN) was upgraded to C from C- on 3/9/2017 due to an increase in the valuation index, dividend index and growth index. Operating cash flow increased 141.68% from $811M to $1.96B, and earnings per share increased from $0.8 to $1.45.
AstraZeneca PLC (AZN) was upgraded to C from C- on 3/9/2017 due to an increase in the valuation index, dividend index and growth index. Operating cash flow increased 141.68% from $811M to $1.96B, and earnings per share increased from $0.8 to $1.45.
C
Hold
2/2/2017Downgrade
AstraZeneca PLC (AZN) was downgraded to C- from C on 2/2/2017 due to a decline in the total return index and volatility index.
AstraZeneca PLC (AZN) was downgraded to C- from C on 2/2/2017 due to a decline in the total return index and volatility index.
C
Hold
1/18/2017Upgraded
AstraZeneca PLC (AZN) was upgraded to C from C- on 1/18/2017 due to a major increase in the valuation index.
AstraZeneca PLC (AZN) was upgraded to C from C- on 1/18/2017 due to a major increase in the valuation index.
C
Hold
1/3/2017Downgrade
AstraZeneca PLC (AZN) was downgraded to C- from C on 1/3/2017 due to a large decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.76 to 0.66, and debt to equity increased from 1.31 to 1.35.
AstraZeneca PLC (AZN) was downgraded to C- from C on 1/3/2017 due to a large decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.76 to 0.66, and debt to equity increased from 1.31 to 1.35.
C
Hold
1/12/2016Downgrade
AstraZeneca PLC (AZN) was downgraded to C from C+ on 1/12/2016 due to a decline in the total return index and volatility index.
AstraZeneca PLC (AZN) was downgraded to C from C+ on 1/12/2016 due to a decline in the total return index and volatility index.
C
Hold
12/28/2015Upgraded
AstraZeneca PLC (AZN) was upgraded to C+ from C on 12/28/2015 due to a large increase in the valuation index, total return index and growth index. Operating cash flow increased 61.57% from $1.08B to $1.75B, EBIT increased 19.52% from $1.16B to $1.38B, and earnings per share increased from $0.275 to $0.3.
AstraZeneca PLC (AZN) was upgraded to C+ from C on 12/28/2015 due to a large increase in the valuation index, total return index and growth index. Operating cash flow increased 61.57% from $1.08B to $1.75B, EBIT increased 19.52% from $1.16B to $1.38B, and earnings per share increased from $0.275 to $0.3.
C
Hold
7/31/2015Downgrade
AstraZeneca PLC (AZN) was downgraded to C from C+ on 7/31/2015 due to a major decline in the valuation index, efficiency index and volatility index.
AstraZeneca PLC (AZN) was downgraded to C from C+ on 7/31/2015 due to a major decline in the valuation index, efficiency index and volatility index.
C
Hold
7/24/2015Upgraded
AstraZeneca PLC (AZN) was upgraded to C+ from C on 7/24/2015 due to a major increase in the valuation index and growth index.
AstraZeneca PLC (AZN) was upgraded to C+ from C on 7/24/2015 due to a major increase in the valuation index and growth index.
C
Hold
11/7/2014Downgrade
AstraZeneca PLC (AZN) was downgraded to C from C+ on 11/7/2014 due to a noticeable decline in the valuation index, growth index and dividend index. Earnings per share declined from $0.63 to $0.2, EBIT declined 30.8% from $1.53B to $1.06B, and operating cash flow declined 6.2% from $2.08B to $1.95B.
AstraZeneca PLC (AZN) was downgraded to C from C+ on 11/7/2014 due to a noticeable decline in the valuation index, growth index and dividend index. Earnings per share declined from $0.63 to $0.2, EBIT declined 30.8% from $1.53B to $1.06B, and operating cash flow declined 6.2% from $2.08B to $1.95B.
C
Hold
11/3/2014Downgrade
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 11/3/2014 due to a noticeable decline in the volatility index and valuation index.
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 11/3/2014 due to a noticeable decline in the volatility index and valuation index.
B
Buy
10/8/2014Upgraded
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 10/8/2014 due to an increase in the volatility index, valuation index and total return index.
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 10/8/2014 due to an increase in the volatility index, valuation index and total return index.
C
Hold
9/2/2014Downgrade
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 9/2/2014 due to a decline in the valuation index and dividend index.
AstraZeneca PLC (AZN) was downgraded to C+ from B- on 9/2/2014 due to a decline in the valuation index and dividend index.
B
Buy
8/15/2014Upgraded
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 8/15/2014 due to an increase in the valuation index, dividend index and volatility index.
AstraZeneca PLC (AZN) was upgraded to B- from C+ on 8/15/2014 due to an increase in the valuation index, dividend index and volatility index.
C
Hold
8/1/2014Upgraded
AstraZeneca PLC (AZN) was upgraded to C+ from C on 8/1/2014 due to a noticeable increase in the growth index, dividend index and solvency index. Operating cash flow increased 75.15% from $1.19B to $2.08B, earnings per share increased from $0.4 to $0.63, and EBIT increased 16.05% from $1.32B to $1.53B.
AstraZeneca PLC (AZN) was upgraded to C+ from C on 8/1/2014 due to a noticeable increase in the growth index, dividend index and solvency index. Operating cash flow increased 75.15% from $1.19B to $2.08B, earnings per share increased from $0.4 to $0.63, and EBIT increased 16.05% from $1.32B to $1.53B.
C
Hold
4/25/2014Downgrade
AstraZeneca PLC (AZN) was downgraded to C from B on 4/25/2014 due to a significant decline in the valuation index, growth index and solvency index. Earnings per share declined from -$0.4179 to $0.4, operating cash flow declined 52.1% from $2.48B to $1.19B, and the quick ratio declined from 1 to 0.82.
AstraZeneca PLC (AZN) was downgraded to C from B on 4/25/2014 due to a significant decline in the valuation index, growth index and solvency index. Earnings per share declined from -$0.4179 to $0.4, operating cash flow declined 52.1% from $2.48B to $1.19B, and the quick ratio declined from 1 to 0.82.
NASDAQ
04/29/2024 12:08PM Eastern
Quotes delayed
